Two Reforms, One Imperative, India’s Parallel Struggles to Regulate AI Content and Pharmaceutical Quality in an Age of Systemic Risk
On the surface, they could not be more different. One concerns the ethereal realm of synthetic media—deepfakes, AI-generated text, and algorithmically produced imagery that blurs the boundary between authentic and manufactured reality. The other concerns the material world of pharmaceutical manufacturing—the chemical composition of tablets, the sterility of injectables, the integrity of supply chains that stretch from bulk drug factories in Himachal Pradesh to hospital pharmacies in Lagos and Lima. One is governed by regulations that come into force this month, a response to the explosive proliferation of generative AI tools. The other is the subject of a long-overdue reform proposal, an acknowledgment that India’s pharmaceutical regulatory apparatus has failed to keep pace with the industry it is meant to oversee.
Yet these two domains, seemingly disparate, are united by a common predicament. Both confront forms of systemic risk that did not exist, or existed only at the margins, a decade ago. Both require regulatory frameworks that are anticipatory rather than reactive, capable of addressing threats before they materialise rather than merely punishing violations after the fact. Both demand a reconceptualisation of the regulator’s role—from a passive arbiter of compliance to an active participant in the construction of markets, technologies, and professional norms. And both illustrate, with unusual clarity, the limitations of India’s existing regulatory architecture and the scale of the institutional transformation required to overcome them.
The new rules on AI-generated content, scheduled to take effect later this month, represent a significant advance in the governance of synthetic media. They require digital platforms to label all synthetically created content, to maintain tracers identifying content creators and the tools they used, to periodically warn users about the penalties for AI misuse, and to dramatically accelerate takedown timelines for harmful content—in some cases, from days to hours. These obligations are not, as the accompanying editorial notes, “beyond technical and operational capabilities of platforms.” They are demanding but feasible, intrusive but justified, complex but necessary.
The proposed reforms to the Central Drugs Standard Control Organisation (CDSCO), articulated in the Union Budget speech and elaborated in the accompanying analysis, are no less ambitious. They envision a fundamental restructuring of India’s pharmaceutical regulatory apparatus: a shift from a manufacturing-centric compliance model to a public health-oriented outcomes model; the replacement of pharmacy-specialist bureaucrats with multidisciplinary teams led by medical professionals; the establishment of CDSCO as an independent regulator, detached from the Directorate General of Health Services; and the creation of a coordinated federal framework that integrates central and state oversight into a coherent system of checks and balances.
Both reforms are, in their respective domains, long overdue. Both have been delayed by bureaucratic inertia, industry resistance, and the sheer difficulty of institutional transformation. Both now face the challenge of implementation—the translation of policy intent into operational reality, of legal text into institutional practice. And both will be judged not by the elegance of their design but by the effectiveness of their execution.
The Deepfake Dilemma: Why Labelling Is Not Overkill
The case for mandatory labelling of AI-generated content rests on a single, foundational premise: consumers are entitled to know the origin of the media they consume. This premise is not novel; it underlies centuries-old prohibitions on forgery and misattribution, modern trademark and copyright law, and the emerging jurisprudence of digital rights. What is novel is the scale and sophistication of the technology that now enables the creation of synthetic content that is, to the untrained eye, indistinguishable from authentic human production.
The harms that flow from unlabelled synthetic content are diverse and well-documented. Deepfake videos can be used to harass and defame individuals, fabricating evidence of actions that never occurred. AI-generated text can be deployed in coordinated disinformation campaigns, flooding public discourse with fabricated narratives and counterfeit consensus. Synthetic audio can impersonate corporate executives, political leaders, and family members, facilitating fraud and manipulation. These are not hypothetical risks; they are present realities, already causing measurable harm to individuals, institutions, and democratic processes.
The regulatory response embodied in the new rules is calibrated to address these harms without imposing disproportionate burdens on legitimate AI applications. The labelling requirement does not prohibit the creation or distribution of synthetic content; it merely requires that such content be identified as synthetic. This is not censorship; it is consumer protection. It does not restrict freedom of expression; it enhances the informational environment in which expression occurs.
The editorial’s insistence that these requirements are “not beyond technical and operational capabilities of platforms” is an important corrective to the inevitable industry pushback. The major digital platforms already possess sophisticated content moderation systems, including automated detection algorithms and human review teams. They already label certain categories of content—advertising, sponsored posts, manipulated media—in accordance with their own policies and, in some jurisdictions, regulatory requirements. Extending these capabilities to cover all synthetically generated content is a matter of will, not feasibility.
The more challenging question is whether the labelling requirement, even if fully implemented, will be sufficient to address the harms of synthetic media. The experience of content moderation in other domains—hate speech, misinformation, copyright infringement—suggests that labelling alone is rarely adequate. Malicious actors will seek to evade detection; platforms will struggle to scale their enforcement; bad-faith users will exploit the inevitable gaps between policy and practice. The accelerated takedown timelines are a recognition of these limitations, providing a mechanism for rapid removal of content that evades the labelling requirement.
Yet even accelerated takedown is a remedial, not preventive, measure. By the time content is identified as harmful and removed, it may already have been viewed, shared, and internalised by millions of users. The damage, once done, cannot be undone. This is the fundamental limitation of all content moderation regimes: they operate after the fact, responding to harms that have already occurred.
The only genuinely preventive measure is to reduce the supply of malicious synthetic content at its source. This requires the identification and accountability of content creators—precisely the function served by the tracer requirements in the new rules. By requiring platforms to maintain records linking synthetic content to its creators and the tools used to generate it, the regulations create a deterrent effect. Creators of malicious content can no longer rely on anonymity; they face the risk of identification, exposure, and legal consequences.
This is not, as some critics have charged, an invasion of privacy or an undue burden on legitimate creators. It is a proportional response to a demonstrable harm, calibrated to the scale and sophistication of the technology that enables it. The editorial’s characterisation of the rules as “timely regulatory intervention” is, if anything, understated. Given the accelerating capabilities of generative AI and the evident inadequacy of voluntary industry self-regulation, the intervention is not merely timely but urgent.
The CDSCO Conundrum: From Manufacturing Compliance to Public Health Outcomes
If the AI content regulations represent a response to a newly emergent risk, the CDSCO reforms represent a response to a long-standing institutional failure. India’s pharmaceutical regulatory apparatus has not kept pace with the transformation of the industry it is meant to oversee.
The limitations of the current system are structural and systemic. CDSCO is not an independent regulator but an attached office of the Directorate General of Health Services, embedded within the government apparatus and subject to the constraints of bureaucratic hierarchy and political oversight. Its personnel are drawn from the pharmacy specialisation of the central services, possessing technical expertise in pharmaceutical science but lacking the multidisciplinary training—in medicine, law, economics, and public administration—that modern drug regulation requires. Its jurisdiction is fragmented, with central oversight of new drug approvals and manufacturing licences for a limited category of products, while state regulators exercise independent authority over most manufacturing facilities and all pharmacies. This fragmentation produces regulatory arbitrage, as manufacturers locate facilities in states with weaker enforcement regimes, and accountability deficits, as central and state authorities blame each other for failures in oversight.
The consequences of these structural deficiencies are not merely theoretical. They are measured in avoidable deaths, preventable injuries, and avoidable damage to India’s reputation as a supplier of pharmaceutical products. The spate of contaminated paediatric cough syrups that killed hundreds of children in Gambia, Uzbekistan, and Cameroon between 2022 and 2023 was not an isolated incident; it was a predictable outcome of a regulatory system that prioritises manufacturing compliance over public health outcomes, that lacks the capacity and independence to enforce quality standards consistently, and that permits substandard manufacturers to operate with impunity.
The proposed reforms address these deficiencies at the level of institutional design. The shift from manufacturing-centric compliance to public health-oriented outcomes is not merely a change in regulatory philosophy; it is a redefinition of the regulator’s mission. The goal is no longer to verify that facilities meet specified technical standards but to ensure that patients receive safe, effective, and affordable medicines. This redefinition has profound implications for every aspect of regulatory practice: the criteria for product approval, the methods of facility inspection, the metrics for performance evaluation, and the qualifications and training of regulatory personnel.
The proposal to replace pharmacy-specialist bureaucrats with multidisciplinary teams led by medical professionals is equally consequential. Drug regulation is not merely a technical exercise in pharmaceutical chemistry; it requires the integration of diverse forms of expertise—clinical medicine to evaluate therapeutic efficacy, epidemiology to assess population-level risks and benefits, pharmacology to understand mechanisms of action and interaction, law to interpret statutory requirements and precedent, economics to weigh costs and benefits, ethics to navigate the inherent tensions between innovation and access. A regulatory authority staffed exclusively by pharmacy specialists is structurally incapable of performing this integrative function.
The most ambitious element of the reform agenda is the proposal to recast CDSCO as an independent regulator, detached from the Directorate General of Health Services and operating under a statutory mandate with functional autonomy. This is not merely an administrative reorganisation; it is a constitutional claim about the proper relationship between the regulatory state and the industries it oversees. An independent regulator, insulated from day-to-day political interference and equipped with its own rulemaking, enforcement, and adjudicatory powers, is better positioned to resist industry capture, to make scientifically grounded decisions without regard to political expediency, and to be held accountable for outcomes rather than outputs.
The challenge, as the editorial notes, is to “avoid half measures.” The history of Indian regulatory reform is replete with examples of ambitious proposals that were diluted in implementation, undermined by bureaucratic resistance, or simply abandoned when confronted with industry opposition or political indifference. The CDSCO reforms will succeed only if they are pursued with sustained commitment, adequate resourcing, and genuine political will.
The Convergence: Systemic Risk and Institutional Capacity
The parallel consideration of AI content regulation and pharmaceutical regulatory reform is not merely a convenience of editorial juxtaposition; it reflects a deeper convergence in the nature of contemporary governance challenges.
Both domains are characterised by rapid technological change that outpaces the capacity of traditional regulatory frameworks. Generative AI did not exist as a mass-market technology five years ago; the pharmaceutical industry of 2026 is fundamentally different from the industry of 1996, let alone 1966. Both domains involve complex, globalised supply chains that extend beyond the jurisdictional reach of any single regulator. Synthetic content created in one jurisdiction can be distributed instantly worldwide; active pharmaceutical ingredients manufactured in India are incorporated into finished dosage forms in dozens of countries. Both domains are characterised by asymmetric information between producers and regulators, with regulated entities possessing vastly superior knowledge of their own products, processes, and risks.
These shared characteristics demand a shared regulatory response: anticipatory rather than reactive, systems-oriented rather than facility-focused, and grounded in the principle that the burden of proof must rest on those who create risks rather than those who are exposed to them. The AI content regulations embody this response in their emphasis on preventive labelling, creator identification, and accelerated takedown. The CDSCO reforms embody it in their emphasis on public health outcomes, multidisciplinary expertise, and institutional independence.
Yet the most important lesson of this convergence is that regulatory capacity is not a luxury but a necessity. In an age of systemic risk, the choice is not between regulation and freedom but between effective regulation and ineffective regulation. The costs of ineffective regulation are not abstract; they are measured in manipulated elections, poisoned children, and destroyed trust in the institutions that are meant to protect us.
India has an opportunity, in both domains, to build regulatory institutions that are fit for purpose. The AI content regulations are among the most advanced in the world, placing India alongside the European Union and China in the vanguard of synthetic media governance. The CDSCO reforms, if fully implemented, would create a pharmaceutical regulatory apparatus that meets global best practices and restores confidence in Indian-made medicines.
The opportunity must be seized. The costs of delay, dilution, and half-measures are too high to bear.
Q&A Section
Q1: What are the key provisions of India’s new regulations on AI-generated content, and what rationale justifies their implementation?
A1: The regulations, effective later this month, impose several obligations on digital platforms. First, labelling: all synthetically created content must be clearly identified as such, enabling consumer differentiation between authentic and AI-generated material. Second, tracers: platforms must maintain records linking synthetic content to its creators and the tools used to generate it, enabling accountability and deterring malicious use. Third, user warnings: platforms must periodically warn users about penalties for misusing AI in content generation. Fourth, accelerated takedown: timelines for removing harmful content are dramatically compressed, in some cases from days to hours. The rationale is that consumers are entitled to know the origin of the media they consume. This is not censorship but consumer protection; it does not restrict legitimate AI applications but ensures transparency. The harms of unlabelled synthetic content are well-documented and include deepfake harassment, coordinated disinformation campaigns, and voice-impersonation fraud. The regulations are calibrated to address these harms without imposing disproportionate burdens, and the editorial argues they are “not beyond technical and operational capabilities of platforms”—a matter of will, not feasibility.
Q2: What are the principal structural deficiencies of India’s current pharmaceutical regulatory system, as identified in the analysis?
A2: The analysis identifies four interconnected structural deficiencies. First, lack of independence: CDSCO is not an independent regulator but an “attached office” of the Directorate General of Health Services, embedded within government bureaucracy and subject to political interference and hierarchical constraints. Second, mono-disciplinary staffing: CDSCO is manned by pharmacy-specialist bureaucrats, lacking the multidisciplinary expertise—medicine, law, economics, public administration, ethics—that modern drug regulation requires. Third, federal fragmentation: CDSCO oversees imports, new drug approvals, and manufacturing licences for a limited category of products, while state regulators exercise independent authority over most manufacturing facilities and all pharmacies. This creates regulatory arbitrage (manufacturers locating in weak-enforcement states) and accountability deficits (central and state authorities blaming each other). Fourth, misplaced regulatory philosophy: the system focuses on manufacturing compliance (verifying that facilities meet technical standards) rather than public health outcomes (ensuring patients receive safe, effective, affordable medicines). These deficiencies are not theoretical; they have produced measurable harms, including the export of contaminated paediatric cough syrups that killed hundreds of children in multiple countries.
Q3: What specific reforms are proposed to address CDSCO’s deficiencies, and what is the significance of “avoiding half measures”?
A3: The proposed reforms address deficiencies at the level of institutional design. First, mission redefinition: shift regulatory philosophy from manufacturing-centric compliance to public health-oriented outcomes, fundamentally changing approval criteria, inspection methods, performance metrics, and personnel qualifications. Second, multidisciplinary staffing: replace pharmacy-specialist bureaucrats with teams integrating clinical medicine, epidemiology, pharmacology, law, economics, and ethics, led by medical professionals. Third, institutional independence: recast CDSCO as an independent regulator, detached from the Directorate General of Health Services, with statutory mandate, functional autonomy, and its own rulemaking, enforcement, and adjudicatory powers. Fourth, federal coordination: transform the current fragmented system of competing central and state authorities into an integrated framework of checks and balances.
“Avoiding half measures” is significant because the history of Indian regulatory reform is replete with ambitious proposals diluted in implementation, undermined by bureaucratic resistance, or abandoned when confronted with industry opposition. The editorial warns that piecemeal adjustments—tinkering with staffing rules without granting independence, or declaring a new regulatory philosophy without restructuring institutional incentives—will fail. Success requires sustained commitment, adequate resourcing, and genuine political will to complete the transformation rather than declare victory prematurely.
Q4: What common characteristics do AI content regulation and pharmaceutical regulation share that make them “systemic risk” governance challenges?
A4: Both domains share four characteristics that distinguish them from traditional regulatory challenges. First, rapid technological change: Generative AI did not exist as a mass-market technology five years ago; pharmaceutical manufacturing has been transformed by biotechnology, continuous manufacturing, and complex global supply chains. Traditional reactive regulation cannot keep pace. Second, globalised supply chains: Synthetic content created in one jurisdiction is distributed instantly worldwide; active pharmaceutical ingredients manufactured in India are incorporated into finished dosage forms in dozens of countries. No single regulator has comprehensive jurisdiction. Third, asymmetric information: Regulated entities possess vastly superior knowledge of their own products, processes, and risks than regulators. This information asymmetry enables exploitation of regulatory gaps and delays detection of harms. Fourth, irreversibility of harm: By the time malicious synthetic content is identified and removed, it may have been viewed and internalised by millions; by the time contaminated medicines are detected, they may have caused deaths that cannot be undone. These characteristics demand a shared regulatory response: anticipatory rather than reactive, systems-oriented rather than facility-focused, and grounded in the principle that the burden of proof must rest on risk-creators rather than risk-bearers. The AI content regulations (preventive labelling, creator identification, accelerated takedown) and CDSCO reforms (public health outcomes, multidisciplinary expertise, institutional independence) embody this response.
Q5: Why does the editorial argue that the choice is not between regulation and freedom but between effective regulation and ineffective regulation?
A5: This argument challenges the familiar framing of regulation as a trade-off between public protection and individual liberty. The editorial contends that this framing is obsolete in an age of systemic risk. The absence of effective regulation does not produce freedom; it produces exposure to unconstrained harms generated by those with the power and incentive to exploit regulatory gaps. Unregulated AI content platforms do not maximise free expression; they enable coordinated disinformation campaigns that degrade the informational environment for all users. Unregulated pharmaceutical manufacturers do not maximise market freedom; they export contaminated products that kill children and destroy the reputation of an entire industry.
The choice, therefore, is not between regulation and its absence. Regulation is inevitable in complex, technologically advanced societies; the only question is who designs it, whom it benefits, and how effectively it achieves its stated purposes. Ineffective regulation—captured by industry, under-resourced, fragmented in jurisdiction, misdirected in philosophy—produces the worst of both worlds: the compliance costs and bureaucratic burdens of regulation without the protective benefits. Effective regulation, by contrast, can enhance freedom by creating the conditions under which individuals can trust the information they consume and the medicines they take.
This reframing has profound implications. It shifts the burden of proof from regulators (who must justify each intervention) to regulated entities (who must demonstrate that self-regulation or market discipline adequately protects public interests). It redefines regulatory failure not as the presence of regulation but as its ineffectiveness. It insists that the question is not “How much regulation?” but “What kind of regulation, designed by whom, and enforced how?” The editorial’s conclusion—that the costs of delay, dilution, and half-measures are too high to bear—follows directly from this reframing.
